Advertisement

Journal of Neurology

, Volume 265, Issue 5, pp 1123–1123 | Cite as

Correction to: Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation

  • E. C. Tallantyre
  • D. H. Whittam
  • S. Jolles
  • D. Paling
  • C. Constantinescu
  • N. P. Robertson
  • A. Jacob
Open Access
Correction
  • 378 Downloads

Correction to: Journal of Neurology  https://doi.org/10.1007/s00415-018-8812-0

In the original article, the co-author’s family name has been published incorrectly. The correct family name should be Constantinescu.

Notes

Compliance with ethical standards

Ethical standards

This study has been approved by the local institutional review board and has, therefore, been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Conflicts of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

References

  1. 1.
    Genzyme (2016) Lemtrada [prescribing information]. Genzyme Corporation, CambridgeGoogle Scholar
  2. 2.
    Cohen JA, Coles AJ, Arnold DL et al (2012) CARE MS I Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380:1819–1828.  https://doi.org/10.1016/S0140-6736(12)61769-3 CrossRefPubMedGoogle Scholar
  3. 3.
    Coles AJ, Twyman CL, Arnold DL et al (2012) CARE MS II Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380:1829–1839.  https://doi.org/10.1016/S0140-6736(12)61768-1 CrossRefPubMedGoogle Scholar
  4. 4.
    Havrdova E, Arnold DL, Cohen JA et al (2017) Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy. Neurology 89:1107–1116.  https://doi.org/10.1212/WNL.0000000000004313 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Coles AJ, Cohen JA, Fox E et al (2017) Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings. Neurology 89:1117–1126.  https://doi.org/10.1212/WNL.0000000000004354 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Al-Sawaf O, Fischer K, Herling CD et al (2017) Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial. Eur J Haematol 98:254–262.  https://doi.org/10.1111/ejh.12825 CrossRefPubMedGoogle Scholar
  7. 7.
    Osterborg A, Foa R, Bezares RF et al (2009) Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia 23:1980–1988.  https://doi.org/10.1038/leu.2009.146 CrossRefPubMedGoogle Scholar
  8. 8.
    Sylvan ES, Lundin J, Ipek M et al (2014) Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL)-a single region experience on consecutive patients. Ann Hematol 83:1725–1733.  https://doi.org/10.1007/s00277-014-2105-1 CrossRefGoogle Scholar
  9. 9.
    Morgan RD, O’Callaghan JM, Knight SR et al (2012) Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis. Transplantation 93:1179–1188.  https://doi.org/10.1097/TP.0b013e318257ad41 CrossRefPubMedGoogle Scholar
  10. 10.
    Van der Zwan M, Baan CC, Van Gelder T et al (2018) Review of the clinical pharmacokinetics and pharmacodynamics of alemtuzumab and its use in kidney transplantation. Clin Pharmacokinet 57:191–207.  https://doi.org/10.1007/s40262-017-0573-x CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s) 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • E. C. Tallantyre
    • 1
    • 2
  • D. H. Whittam
    • 3
    • 4
  • S. Jolles
    • 1
    • 2
  • D. Paling
    • 5
    • 6
  • C. Constantinescu
    • 7
  • N. P. Robertson
    • 1
    • 2
  • A. Jacob
    • 3
    • 4
  1. 1.University Hospital of WalesCardiffUK
  2. 2.Cardiff University School of MedicineCardiffUK
  3. 3.The Walton Centre NHS TrustLiverpoolUK
  4. 4.University of LiverpoolLiverpoolUK
  5. 5.NIHR Sheffield Biomedical Research Centre (Translational Neuroscience)SheffieldUK
  6. 6.Royal Hallamshire HospitalSheffieldUK
  7. 7.University of NottinghamNottinghamUK

Personalised recommendations